Clinical Trial Update: Study to Evaluate Safety and Efficacy of ASC42 Combined With ETV and PEG-IFN α-2a in Subjects With HBV [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and efficacy of ASC42 with ETV and PEG-IFN α-2a in chronic hepatitis B completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• ASC42
• ETV (entecavir)
• PEG-IFN α-2a (pegylated interferon alfa-2a)

Snippet

Sponsor: Ascletis Pharmaceuticals Co., Ltd. | Conditions: Hepatitis B, Chronic | Phase 2 | Status: COMPLETED